At the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is no surprise that two-years on, the number of therapeutic options in cancer care is growin
In the first of two articles, Theano Anastasopoulou uses behavioural economics to understand and investigate how physicians make decisions and thereby improve the take-up of new medicines.
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
